Bioresonance for Childhood Eczema: What a Sham-Controlled Trial Found
When a child's eczema remains difficult, a treatment described as correcting energy or frequencies can sound appealing. The important question is whether the procedure adds benefit beyond usual care and an inactive version of the same experience. A small blinded study of bioresonance addressed that question directly, rather than relying on improvement reported after treatment alone.
A device comparison during the same inpatient care
The 1997 trial studied bioresonance, also called biophysical information therapy. The original paper reports 36 recruited children and 32 evaluated, aged 1.5–16.8 years. They received conventional inpatient eczema care in Davos for four to six weeks, plus active or sham bioresonance under double blinding. Four children were excluded from analysis.
Both groups improved. Mean Costa severity-score reduction was 12.5 points with active treatment and 6.7 with sham, but the comparison was nonsignificant, p=0.2330. Itching and sleep comparisons were also nonsignificant, p=0.1166 and p=0.9165. The investigators found no significant added measurable benefit from bioresonance, including longer-term outcomes.
Improvement during treatment is not the same as a device effect
| Observation | Question answered by the sham comparison |
|---|---|
| Children improved during admission | Did active bioresonance add benefit to the shared care? |
| The active group had a larger numerical score change | Was that difference statistically persuasive in this sample? |
| Both groups received eczema treatment | Can improvement be attributed to the device alone? |
| Thirty-two children were evaluated | How much uncertainty and exclusion bias remain? |
A sham procedure helps preserve aspects of the treatment experience while removing the proposed active component. That makes it more informative than comparing a testimonial with no treatment record. Here, improvement shared by both groups cannot establish that the bioresonance mechanism worked. It is consistent with the value of the wider care setting and treatment package, without identifying which part of that package mattered most.
The numerical difference should still be reported, alongside its uncertainty. Calling it proof of benefit would ignore the actual comparison; calling the study proof that every conceivable benefit is exactly zero would go beyond it. The useful conclusion is that this trial did not demonstrate an added clinical benefit. Our guide to reading eczema trials discusses that distinction.
The inpatient setting limits what can be generalized
This was a small specialist-center study with concurrent care and a high-altitude environment. It was not a large evaluation of every commercial device or an ordinary outpatient service. Those limits should be stated without turning missing evidence into positive evidence. If a provider proposes a different device or program, ask for controlled results for that exact intervention and the outcome they promise.
The homeopathy evidence article covers a separate intervention and should not be merged with bioresonance. Evidence for one complementary approach cannot establish another's benefit. Likewise, a device-treatment study is not evidence that an allergy has been identified or removed.
Ask what the proposed service changes in the plan
Before spending time and money, ask what improvement is expected, how it will be measured, what controlled evidence supports it and how the service fits with prescribed care. A claim to cure eczema deserves evidence far stronger than a before-and-after story. Do not let testing or treatment appointments delay review of a worsening rash or disrupt a child's effective plan.
AAD describes an individualized eczema plan built around appropriate skin care, trigger management and treatment. Parents of very young children can also use our infant diagnosis and care-plan guide to prepare for a clinical review. The goal is a plan that helps the child and family, with clear evidence about what each proposed addition contributes.
Compare the related evidence
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational information supports discussion with a qualified clinician and does not diagnose or prescribe. The AI-created sports product image is an editorial illustration, not a patient photograph or clinical result.